WITHIN-DRUG BENEFIT/RISK EVALUATION OF OLANZAPINE LONG-ACTING INJECTION AT 1 AND 2 YEARS OF TREATMENT
Publication/Presentation Date
4-2012
Volume
136
Issue
1
First Page
262
Last Page
263
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS